Autism Spectrum Disorder Trial, Recruiting NCT06060860 Sponsor: University of North Carolina, Chapel Hill Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Autism Spectrum Disorder Trial, Recruiting

NCT06060860
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have both depression and/or anxiety, shown by a score of 10 or higher on a questionnaire called the PHQ-ADS
  • People who currently live in North Carolina or Virginia
  • People who are able to attend therapy sessions by video or phone (telehealth)
  • People who speak English
  • People who either have a formal professional diagnosis of autism, or who score at or above the clinical cut-off on an autism screening tool called the Social Responsiveness Scale (SRS-2)

Who may not be able to join:

  • People who are currently experiencing a mental state that would prevent them from understanding and agreeing to take part — such as an episode of acute psychosis, being under the influence of substances, or a manic episode
  • People who are assessed as being at immediate risk of suicide

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Laura Klinger, PhD, University of North Carolina, Chapel Hill

Phone: (919) 966-8183

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
17 January 2024
Est. completion
15 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in anxiety and depression symptoms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov